GlaxoSmithKline Pharmaceutical, a leading MNC in India, suffered a setback during the 15 months period ended March 2015 and its consolidated net profit on an annual basis decreased by 20.9 per cent to Rs.381.12 crore from Rs.481.67 crore in the year ended December 2013.
Its annual consolidated net sales improved marginally by 3.1 per cent to Rs.2,618 crore from Rs.2,538 crore. EPS for 15 months period worked out to Rs.56.2 as against Rs.56.9 in the last year. The board of directors suggested equity dividend of Rs.62.50 per share for the year 2014-15. The company attributed lower sales growth to "supply constraints".
Its standalone net sales for the quarter ended March 2015 improved by 2.3 per cent to Rs.613.47 crore for the quarter of 2014-15 fiscal, compared with Rs 599.85 crore in the year-ago period . Its standalone net profit increased 6.5 per cent to Rs.102.85 crore from Rs.96.54 crore. Its standalone net sales for the 15 months period ended amounted to Rs.3,253 crore as compared to Rs.2,520 crore in the previous year of 12 months period. Its standalone net profit, however decreased to Rs.471.65 crore from Rs.501.88 crore.
Subscribe to PharmaTutor News Alerts by Email >>
